ENDPOINTS

GLP-1s may cut cancer risk; Gyre’s stock falls after hepatitis C data and offering

Plus, news about Sanofi, Servier, BioNova, Arcutis, Roche, Satellos Bioscience, Fore Biotherapeutics, Cinclus Pharma and Zentiva: GLP-1 drugs could cut cancer risk: An academic, observational study published Friday ahead of ASCO’s annual meeting found that ...

May 23, 2025 - 15:34
 0
GLP-1s may cut cancer risk; Gyre’s stock falls after hepatitis C data and offering
Plus, news about Sanofi, Servier, BioNova, Arcutis, Roche, Satellos Bioscience, Fore Biotherapeutics, Cinclus Pharma and Zentiva: GLP-1 drugs could cut cancer risk: An academic, observational study published Friday ahead of ASCO’s annual meeting found that ...
Read More

Tags:

Previous Article

When the sea moves inland: A global climate wake-up call from Bangladesh's Delta

Next Article

Bad Provider Data Is Delaying Care and Driving Up Costs, CAQH CEO Warns

Related Posts

Trump administration reveals 'most favored nation' drug price targets

Trump administration reveals 'most favored nation' drug...

May 20, 2025  0

The ‘MAHA report’: What it says about vaccines, medicine and the pharma industry

The ‘MAHA report’: What it says about vaccines, medicin...

May 22, 2025  0

Cigna, Novo Nordisk offer lower GLP-1 prices

Cigna, Novo Nordisk offer lower GLP-1 prices

May 22, 2025  0